• (PLX AI) – Bavarian Nordic is on track to present phase 2 data on its Covid-19 vaccine trial next month, which could be a major de-risking event for the stock, analysts at Nordea said.
  • • Bavarian Nordic has said that ongoing dialogue with regulators about a future phase 3 trial has been constructive
  • • Nordea keeps a buy rating on Bavarian, with price target cut to DKK 563 from DKK 571
  • • The vaccine data looks promising compared to competitors, Danske said, even if the phase 3 trial may end up with a small delay
  • • Danske maintains a buy rating on Bavarian, with price target cut to DKK 480 from DKK 500
  • • Bavarian shares are up 2% in Copenhagen

Quelle: PLX AI